Investigational drug · Phase 3
Frexalimab
Also called: SAR441344
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
9
Any phase or sponsor naming "Frexalimab"
First trial start
2021
Jun 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Frexalimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Sclerosis
- Focal Segmental Glomerulosclerosis
- Glomerulonephritis Minimal Lesion
- Kidney Transplant Rejection
- Type 1 Diabetes Mellitus
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Type 1 diabetes · Multiple sclerosis · Lupus (SLE) · Cardiovascular and metabolic · Neurology · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Frexalimab" as an intervention, largest first.
- A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple SclerosisPivotal-lookingNot yet recruiting
SanofiSanofi (SNY)
NCT07930624 · 2,500 participants (planned) · Start Feb 15, 2027 · Primary completion May 16, 2031
Drug: Frexalimab; Frexalimab and 6 more · For: Multiple Sclerosis
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06141473 · 1,655 participants · Start Dec 13, 2023 · Primary completion May 6, 2027
Drug: Frexalimab; Teriflunomide and 5 more · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Homewood, Alabama · 382 sites in all
- Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06141486 · 943 participants · Start Dec 27, 2023 · Primary completion Mar 24, 2028
Drug: Frexalimab; Placebo and 1 more · For: Multiple Sclerosis
Sites: Homewood, Alabama; Scottsdale, Arizona; Berkeley, California · 311 sites in all
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney TransplantationPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07412470 · 526 participants (planned) · Start Mar 13, 2026 · Primary completion Aug 15, 2029
Drug: Frexalimab; Frexalimab and 6 more · For: Kidney Transplant Rejection
Sites: San Francisco, California; Atlanta, Georgia; Hines, Illinois · 73 sites in all
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06111586 · 197 participants · Start Dec 11, 2023 · Primary completion Apr 28, 2027
Drug: Frexalimab; Placebo and 1 more · For: Type 1 Diabetes Mellitus
Sites: San Francisco, California; Aurora, Colorado; Gainesville, Florida · 79 sites in all
- Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07325292 · 160 participants (planned) · Start Jan 14, 2026 · Primary completion Jul 15, 2027
Drug: Frexalimab; Frexalimab and 1 more · For: Multiple Sclerosis
Sites: Cullman, Alabama; Homewood, Alabama; Phoenix, Arizona · 68 sites in all
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT04879628 · 129 participants · Start Jun 7, 2021 · Primary completion Sep 21, 2022
Drug: SAR441344 IV; placebo IV and 3 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Tampa, Florida; Charlotte, North Carolina · 37 sites in all
- Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05039840 · 109 participants · Start Nov 10, 2021 · Primary completion Sep 4, 2026
Drug: SAR441344 IV; SAR441344 SC and 2 more · For: Systemic Lupus Erythematosus
Sites: Vestavia Hills, Alabama; Chandler, Arizona; Mesa, Arizona · 73 sites in all
SanofiSanofi (SNY)
NCT06500702 · 84 participants (planned) · Start Dec 19, 2024 · Primary completion Dec 23, 2026
Drug: frexalimab; brivekimig and 2 more · For: Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion
Sites: Birmingham, Alabama; Orange, California; San Francisco, California · 82 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent-Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design.
Cherkas A, Rotthaeuser B, Porksen N, et al. · Diabetes Obes Metab 2026
- Psychometric validation of PROMIS-Fatigue-MS-8a and MSIS-29v2 questionnaires in relapsing multiple sclerosis participants enrolled in a phase 2 trial of frexalimab.
Vermersch P, Araujo L, Gourlain S, et al. · Mult Scler Relat Disord 2026
- Monoclonal Antibodies as Therapeutic Agents in Autoimmune and Neurodegenerative Diseases of the Central Nervous System: Current Evidence on Molecular Mechanisms and Future Directions.
Skarlis C, Angelopoulou E, Rentzos M, et al. · Int J Mol Sci 2025
- The role of microglia in multiple sclerosis: implications for treatment with Bruton's tyrosine kinase inhibitors.
Vermersch P, Airas L, Berger T, et al. · Front Immunol 2025
- Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes.
Weiskorn J, Weiskorn J, Danne T · Horm Res Paediatr 2025
- Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a review.
Fatima T, Mirza A, Fatima F, et al. · Ann Med Surg (Lond) 2024
Also in development for Multiple Sclerosis
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
- IMU-838Vidofludimus calciumPhase 33 trials
Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- MRI contrast-enhancing agentsPhase 33 trials
Sanofi · Multiple Sclerosis
- KYV-101Phase 32 trials
Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis
- MRI contrast-enhancing preparationsPhase 32 trials
Sanofi · Multiple Sclerosis
- zamtocabtagene autoleucelMB-CART2019.1Phase 25 trials
Miltenyi Biomedicine GmbH · CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis
- Allogeneic umbilical cord mesenchymal stem cellsPhase 23 trials
Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction
- Autologous HB-adMSCsPhase 22 trials
Hope Biosciences LLC · Traumatic Brain Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.